Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL R SALTZSTEIN

Allopathic & Osteopathic Physicians Urology

NPI
1922088947
CMS profile
42094
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$100,766.51

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL R SALTZSTEIN

NPI 1922088947 · CMS profile ID 42094

Allopathic & Osteopathic Physicians / Urology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922088947?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL R SALTZSTEIN, NPI 1922088947, CMS profile ID 42094. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922088947?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DANIEL R SALTZSTEIN, NPI 1922088947, CMS profile ID 42094. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922088947?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DANIEL R SALTZSTEIN, NPI 1922088947, CMS profile ID 42094, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1922088947?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $100,766.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–134 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $6.1404/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886660637 CMS
SN Holdings, LLC $1,050.0004/27/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942783281 CMS
SN Holdings, LLC $1,050.0004/27/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942783283 CMS
Janssen Biotech, Inc. $1,100.0004/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886660501 CMS
Myovant Sciences Inc. $5,525.0004/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941238271 CMS
AstraZeneca Pharmaceuticals LP $1,860.0004/18/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914767825 CMS
Astellas Pharma Global Development $2,340.0004/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925798777 CMS
Axonics, Inc. $11.8604/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958545913 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,248.0003/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930627371 CMS
SN Holdings, LLC $171.5703/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942783253 CMS
SN Holdings, LLC $556.3703/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942783259 CMS
SN Holdings, LLC $70.4403/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942783261 CMS
SN Holdings, LLC $10.7003/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942783263 CMS
SN Holdings, LLC $2,154.2703/31/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942783273 CMS
Dendreon Pharmaceuticals LLC $24.7403/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943105549 CMS
Dendreon Pharmaceuticals LLC $8.4803/23/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943105551 CMS
PFIZER INC. $15.2603/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949083921 CMS
TOLMAR Pharmaceuticals, Inc. $18.4903/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954462191 CMS
Bayer HealthCare Pharmaceuticals Inc. $832.0003/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930598897 CMS
Janssen Scientific Affairs, LLC $757.5003/16/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887273963 CMS
Astellas Pharma US Inc $16.1403/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940139103 CMS
UROVANT SCIENCES INC $18.1003/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 931069001 CMS
Merck Sharp & Dohme LLC $72.0203/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944515733 CMS
Progenics Pharmaceuticals, Inc. $2,275.0002/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938564581 CMS
Myovant Sciences Inc. $19.7202/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941238269 CMS
Janssen Biotech, Inc. $1,100.0002/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886660477 CMS
Janssen Biotech, Inc. $1,100.0002/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886660483 CMS
Myovant Sciences Inc. $5,525.0002/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941238267 CMS
Myovant Sciences Inc. $53.8801/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941238255 CMS
Myovant Sciences Inc. $33.0901/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941238257 CMS
Myovant Sciences Inc. $129.3601/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941238261 CMS
Myovant Sciences Inc. $37.8701/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941238263 CMS
Myovant Sciences Inc. $148.3601/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941238265 CMS
SN Holdings, LLC $500.0001/21/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942783279 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $89,342.73 126
PY2020 $60,525.67 53
PY2021 $92,137.99 76
PY2022 $100,766.51 134
PY2023 $83,631.15 104
PY2024 $65,960.90 89
PY2025 $54,335.52 91

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,270.00 2
PY2025 Principal investigator $237,360.91 24
PY2024 Recipient $330.00 1
PY2024 Principal investigator $83,567.82 21
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $609,600.45 75
PY2022 Principal investigator $1,085,830.84 92
PY2021 Principal investigator $1,563,579.48 121
PY2020 Recipient $1,270.00 2
PY2020 Principal investigator $994,828.89 109
PY2019 Principal investigator $693,024.81 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Blue Earth Diagnostics $3,000.00 12/18/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659113
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,848.93 12/18/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1190305027
Principal investigator 1 Novartis Pharmaceuticals Corporation $33.92 11/15/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment No dispute reported 06/30/2026 1190306611
Principal investigator 1 UROGEN PHARMA, INC. $500.00 10/28/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO P.A.
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1242756719
Principal investigator 1 UROGEN PHARMA, INC. $33.90 10/28/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO P.A.
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1242756721
Principal investigator 1 UROGEN PHARMA, INC. $33.90 10/28/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO P.A.
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1242756723
Principal investigator 1 UROGEN PHARMA, INC. $14.70 10/28/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO P.A.
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1242756725
Principal investigator 1 UROGEN PHARMA, INC. $14.70 10/28/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO P.A.
BL007 - A ROLLOVER STUDY TO FOLLOW THE LONG-TERM OUTCOMES OF PATIENTS FROM STUDY UT001 (FORMERLY TC-UT-03) AND STUDY TC-BC-12 No dispute reported 06/30/2026 1242756727
Principal investigator 1 Blue Earth Diagnostics $56,027.50 09/10/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659131
Principal investigator 1 Blue Earth Diagnostics $42,322.80 08/15/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659129
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,703.17 08/15/2025 Non-covered Recipient Entity
UROLOGY SAN ANTONIO
A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment No dispute reported 06/30/2026 1190308360
Recipient PFIZER INC. $330.00 08/05/2025 Covered Recipient Physician DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726510
Principal investigator 1 Epizyme, Inc. $1,678.75 07/11/2025 Non-covered Recipient Entity
Urology San Antonio
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282383
Principal investigator 1 Epizyme, Inc. $4,366.00 07/11/2025 Non-covered Recipient Entity
Urology San Antonio
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282385
Principal investigator 1 Dendreon Pharmaceuticals LLC $11,700.00 06/30/2025 Non-covered Recipient Entity
SPECIALTY CLINICAL RESEARCH OF ST LOUIS LLC
ProvONE No dispute reported 06/30/2026 1247892254
Principal investigator 1 Blue Earth Diagnostics $5,065.80 06/20/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659125
Principal investigator 1 Epizyme, Inc. $24,212.25 06/20/2025 Non-covered Recipient Entity
Urology San Antonio
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282381
Principal investigator 1 Blue Earth Diagnostics $5,065.80 06/18/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659115
Principal investigator 1 Blue Earth Diagnostics $5,065.80 06/18/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659133
Principal investigator 1 Blue Earth Diagnostics $5,065.80 05/06/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659117
Recipient PFIZER INC. $940.00 04/27/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770802
Principal investigator 1 Blue Earth Diagnostics $5,065.80 03/19/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659119
Principal investigator 1 Blue Earth Diagnostics $12,500.00 02/27/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659127
Principal investigator 1 Blue Earth Diagnostics $5,065.80 02/11/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659121
Principal investigator 1 Blue Earth Diagnostics $5,065.80 01/17/2025 Non-covered Recipient Entity
Urology San Antonio
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1252659123
Principal investigator 1 Epizyme, Inc. $17,909.79 01/08/2025 Non-covered Recipient Entity
Urology San Antonio
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1184282379

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 2
PY2024 Value of interest $368,218.07 2
PY2023 Amount invested $0.00 1
PY2023 Value of interest $363,894.61 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $175,673.26 1
PY2021 Amount invested $100,000.00 1
PY2021 Value of interest $163,125.17 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $84,936.38 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $37,124.34 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 SN Holdings, LLC $0.00 $946.09 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124771653
PY2024 SN Holdings, LLC $0.00 $367,271.98 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124773401
PY2023 SN Holdings, LLC $0.00 $363,894.61 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1032887491
PY2022 SN Holdings, LLC $0.00 $175,673.26 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 941609467
PY2021 SN Holdings, LLC $100,000.00 $163,125.17 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 820125383
PY2020 UroGPO LLC $0.00 $84,936.38 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 737139661
PY2019 UroGPO LLC $0.00 $37,124.34 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 690775241